中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(9): 1757-1766

Experts consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of primary biliary cholangitis

DOI: 10.12449/JCH240907
  • Received Date: 2024-08-10
  • Accepted Date: 2024-08-20
  • Published Date: 2024-09-25
    Abstract
  • Primary biliary cholangitis （PBC） is a chronic autoimmune liver disease. In recent years， related studies in China and globally have provided some evidence-based medical evidence for the integrated traditional Chinese and Western medicine treatment of PBC. Based on the latest diagnosis and treatment experience and guidelines in China and globally， Expert Committee on Hepatology， Doctor Society of Integrative Medicine， Chinese Medical Doctor Association， organized related experts in China to formulate this consensus， in order to provide guidance and reference for clinicians in the diagnosis， TCM syndrome differentiation， and integrated traditional Chinese and Western medicine treatment of PBC.

     

    • FullText(HTML)
  • loading
    • References(70)
  • [1]
    YOU H, MA X, EFE C, et al. APASL clinical practice guidance: The diagnosis and management of patients with primary biliary cholangitis[J]. Hepatol Int, 2022, 16( 1): 1- 23. DOI: 10.1007/s12072-021-10276-6.
    [2]
    YOU H, DUAN WJ, LI SX, et al. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Transl Hepatol, 2023, 11( 3): 736- 746. DOI: 10.14218/JCTH.2022.00347.
    [3]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2018, 69( 1): 394- 419. DOI: 10.1002/hep.30145.
    [4]
    HIRSCHFIELD GM, DYSON JK, ALEXANDER GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67( 9): 1568- 1594. DOI: 10.1136/gutjnl-2017-315259.
    [5]
    YAO JM, GUO JC. Progress in TCM pathogenesis and treatment of primary biliary cholangitis[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 11): 1051- 1053. DOI: 10.3969/j.issn.1005-0264.2021.11.026.

    姚佳敏, 过建春. 原发性胆汁性胆管炎中医病机认识及治疗进展[J]. 中西医结合肝病杂志, 2021, 31( 11): 1051- 1053. DOI: 10.3969/j.issn.1005-0264.2021.11.026.
    [6]
    HUANG ZH, XU WJ, LIU W. Research on traditional Chinese medicine patterns and symptoms of Primary biliary cholangitis based on modern literature[J]. Glob Tradit Chin Med, 2021, 14( 11): 1966- 1975. DOI: 10.3969/j.issn.1674-1749.2021.11.007.

    黄正慧, 徐雯洁, 刘汶. 基于现代文献的原发性胆汁性胆管炎中医证型证候研究[J]. 环球中医药, 2021, 14( 11): 1966- 1975. DOI: 10.3969/j.issn.1674-1749.2021.11.007.
    [7]
    LV TT, CHEN S, LI M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36( 6): 1423- 1434. DOI: 10.1111/jgh.15329.
    [8]
    TRIVELLA J, JOHN BV, LEVY C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment[J]. Hepatol Commun, 2023, 7( 6): e0179. DOI: 10.1097/HC9.0000000000000179.
    [9]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 35- 41. DOI: 10.3760/cma.j.cn112138-20211112-00794.

    中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 35- 41. DOI: 10.3760/cma.j.cn112138-20211112-00794.
    [10]
    ZHANG FC, WANG L, SHUAI ZW, et al. Recommendations for diagnosis and treatment of primary biliary cholangitis in China(2021)[J]. Chin J Intern Med, 2021, 60( 8): 709- 715. DOI: 10.3760/cma.j.cn112138-20210520-00360.

    张奉春, 王立, 帅宗文, 等. 原发性胆汁性胆管炎诊疗规范(2021)[J]. 中华内科杂志, 2021, 60( 8): 709- 715. DOI: 10.3760/cma.j.cn112138-20210520-00360.
    [11]
    LIU ZC, WANG ZL, ZHENG JR, et al. Prevalence of primary biliary cholangitis in the Chinese general population and its influencing factors: A systematic review[J]. J Clin Hepatol, 2023, 39( 2): 325- 332. DOI: 10.3969/j.issn.1001-5256.2023.02.011.

    刘智成, 王资隆, 郑佳睿, 等. 我国一般人群原发性胆汁性胆管炎患病率及其影响因素的系统综述[J]. 临床肝胆病杂志, 2023, 39( 2): 325- 332. DOI: 10.3969/j.issn.1001-5256.2023.02.011.
    [12]
    AL-HARTHY N, KUMAGI T. Natural history and management of primary biliary cirrhosis[J]. Hepat Med, 2012, 4: 61- 71. DOI: 10.2147/HMER.S25998.
    [13]
    CORPECHOT C, ABENAVOLI L, RABAHI N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48( 3): 871- 877. DOI: 10.1002/hep.22428.
    [14]
    PARÉS A, CABALLERÍA L, RODÉS J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid[J]. Gastroenterology, 2006, 130( 3): 715- 720. DOI: 10.1053/j.gastro.2005.12.029.
    [15]
    WANG C, ZHENG XD, JIANG P, et al. Genome-wide association studies of specific antinuclear autoantibody subphenotypes in primary biliary cholangitis[J]. Hepatology, 2019, 70( 1): 294- 307. DOI: 10.1002/hep.30604.
    [16]
    QIU F, WANG C, ZHANG MM, et al. Genetic studies of primary biliary cholangitis in the post-GWAS era[J]. J Clin Hepatol, 2022, 38( 4): 759- 761. DOI: 10.3969/j.issn.1001-5256.2022.04.005.

    邱方, 王婵, 张明明, 等. 后GWAS时代的原发性胆汁性胆管炎的遗传学研究[J]. 临床肝胆病杂志, 2022, 38( 4): 759- 761. DOI: 10.3969/j.issn.1001-5256.2022.04.005.
    [17]
    NI X, WANG XB. Professor Wang xianbo’s experience in treating primary biliary cirrhosis[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 7): 652- 653, 659. DOI: 10.3969/j.issn.1005-0264.2023.007.019.

    倪旭, 王宪波. 王宪波教授治疗原发性胆汁性肝硬化的经验[J]. 中西医结合肝病杂志, 2023, 33( 7): 652- 653, 659. DOI: 10.3969/j.issn.1005-0264.2023.007.019.
    [18]
    ZHOU XZ, ZHANG W, HUANG DW, et al. Relationship between\“deficiency of vital Qi\”and primary bile cholangitis[J]. Liaoning J Tradit Chin Med, 2020, 47( 9): 51- 53. DOI: 10.13192/j.issn.1000-1719.2020.09.017.

    周希禛, 张玮, 黄大未, 等.“正气不足” 与原发性胆汁性胆管炎关系探析[J]. 辽宁中医杂志, 2020, 47( 9): 51- 53. DOI: 10.13192/j.issn.1000-1719.2020.09.017.
    [19]
    DU HB, JIANG YY, XUE YC, et al. Survey on Chinese medicine syndrome of 96 patients with primary biliary cirrhosis[J]. J Tradit Chin Med, 2017, 58( 7): 575- 578. DOI: 10.13288/j.11-2166/r.2017.07.011.

    杜宏波, 江宇泳, 薛亚春, 等. 96例原发性胆汁性肝硬化患者中医证候调查[J]. 中医杂志, 2017, 58( 7): 575- 578. DOI: 10.13288/j.11-2166/r.2017.07.011.
    [20]
    ZHENG YQ, CHEN JJ, CHEN YY, et al. Distribution features of TCM syndrome types and syndrome elements of primary biliary cholangitis: A literature review[J]. J Clin Hepatol, 2018, 34( 4): 814- 819. DOI: 10.3969/j.issn.1001-5256.2018.04.024.

    郑玥琪, 陈建杰, 陈逸云, 等. 原发性胆汁性胆管炎中医证型与证素分布特点文献分析[J]. 临床肝胆病杂志, 2018, 34( 4): 814- 819. DOI: 10.3969/j.issn.1001-5256.2018.04.024.
    [21]
    FAN XL, DAI YY, GAO Q, et al. On“Yin deficiency” and primary biliary cholangitis[J]. J Basic Chin Med, 2018, 24( 6): 739- 741.

    范兴良, 戴瑶瑶, 高勤, 等. 论“阴常不足”与原发性胆汁性胆管炎[J]. 中国中医基础医学杂志, 2018, 24( 6): 739- 741.
    [22]
    YANG JL, ZHANG MZ, ZHANG B. The analysis of TCM syndrome and clinical features for 74 cases patients with primary biliary cirrhosis[J]. Chin J Integr Tradit West Med Liver Dis, 2015, 25( 4): 209- 211. DOI: 10.3969/j.issn.1005-0264.2015.04.006.

    杨将领, 张美珠, 张斌. 74例原发性胆汁性肝硬化患者中医证型及临床特征分析[J]. 中西医结合肝病杂志, 2015, 25( 4): 209- 211. DOI: 10.3969/j.issn.1005-0264.2015.04.006.
    [23]
    ZHENG YQ, CHEN JJ, LU YF, et al. Clinical study on the correlation between traditional Chinese medicine syndrome characteristics and inadequate response to UDCA in patients with primary biliary cholangitis[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29( 5): 402- 405. DOI: 10.3969/j.issn.1005-0264.2019.05.006.

    郑玥琪, 陈建杰, 陆云飞, 等. 原发性胆汁性胆管炎患者中医证候特征与熊去氧胆酸应答不佳的相关性研究[J]. 中西医结合肝病杂志, 2019, 29( 5): 402- 405. DOI: 10.3969/j.issn.1005-0264.2019.05.006.
    [24]
    MIAO HY, ZHENG PY, WANG ZR, et al. Research on TCM syndromes and manifestations of primary biliary cholangitis based on factor analysis and cluster analysis[J]. Shanghai J Tradit Chin Med, 2021, 55( 3): 17- 21, 26. DOI: 10.16305/j.1007-1334.2021.2009081.

    缪虹雨, 郑培永, 王哲睿, 等. 基于因子分析、聚类分析的原发性胆汁性胆管炎中医证候研究[J]. 上海中医药杂志, 2021, 55( 3): 17- 21, 26. DOI: 10.16305/j.1007-1334.2021.2009081.
    [25]
    GORDON SC, WU KH, LINDOR K, et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115( 2): 262- 270. DOI: 10.14309/ajg.0000000000000512.
    [26]
    NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375( 7): 631- 643. DOI: 10.1056/NEJMoa1509840.
    [27]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases[J]. Hepatology, 2022, 75( 4): 1012- 1013. DOI: 10.1002/hep.32117.
    [28]
    ASSIS DN. Advancing second-line treatment for primary biliary cholangitis[J]. N Engl J Med, 2024, 390( 9): 853- 854. DOI: 10.1056/NEJMe2312745.
    [29]
    CORPECHOT C, CHAZOUILLÈRES O, ROUSSEAU A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 378( 23): 2171- 2181. DOI: 10.1056/NEJMoa1714519.
    [30]
    ZHANG Y, LI SN, HE L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: A meta-analysis[J]. Drug Des Devel Ther, 2015, 9: 2757- 2766. DOI: 10.2147/DDDT.S79837.
    [31]
    LIU H, SHI BA. Clinical observation on Xiaoyao Powder combined with ursodeoxycholic acid in the treatment of 33 cases of primary biliary cirrhosis[J]. Hunan J Tradit Chin Med, 2016, 32( 9): 54- 56. DOI: 10.16808/j.cnki.issn1003-7705.2016.09.025.

    刘晗, 施伯安. 逍遥散联合熊去氧胆酸治疗原发性胆汁性肝硬化33例临床观察[J]. 湖南中医杂志, 2016, 32( 9): 54- 56. DOI: 10.16808/j.cnki.issn1003-7705.2016.09.025.
    [32]
    CHEN JL, YANG X, ZHANG Q, et al. Effect of ursodeoxycholic acid with traditional Chinese medicine on biochemical response in patients with primary biliary cholangitis: A real-world cohort study[J]. Chin J Hepatol, 2018, 26( 12): 909- 915. DOI: 10.3760/cma.j.issn.1007-3418.2018.12.007.

    陈佳良, 杨雪, 张群, 等. 熊去氧胆酸联合中药治疗对原发性胆汁性胆管炎患者生物化学应答的影响: 一项基于真实世界的队列研究[J]. 中华肝脏病杂志, 2018, 26( 12): 909- 915. DOI: 10.3760/cma.j.issn.1007-3418.2018.12.007.
    [33]
    LIU Y, DONG ZH. Professor Dong Zhenhua's experience in treating primary biliary cirrhosis[J]. Chin J Clin, 2015, 43( 1): 85- 86. DOI: 10.3969/j.issn.2095-8552.2015.01.036.

    刘颖, 董振华. 董振华教授治疗原发性胆汁性肝硬化的经验[J]. 中国临床医生, 2015, 43( 1): 85- 86. DOI: 10.3969/j.issn.2095-8552.2015.01.036.
    [34]
    JIN H, WANG XJ, ZHAO SJ, et al. Clinical observation of Hexue Rongfu Decoction in the treatment ofpruritus of autoimmune liver diseases[J]. Beijing J Tradit Chin Med, 2024, 43( 6): 590- 593. DOI: 10.16025/j.1674-1307.2024.06.003.

    靳华, 汪晓军, 赵世娇, 等. 和血荣肤汤治疗自身免疫性肝病瘙痒症临床观察[J]. 北京中医药, 2024, 43( 6): 590- 593. DOI: 10.16025/j.1674-1307.2024.06.003.
    [35]
    WANG YX, PENG WW, HUANG JZ, et al. Study on the medication rules of traditional Chinese medicine for treating primary biliary cholangitis based on data mining[J]. Tradit Chin Drug Res Clin Pharmacol, 2022, 33( 8): 1124- 1130. DOI: 10.19378/j.issn.1003-9783.2022.08.017.

    王宇新, 彭文婉, 黄锦桢, 等. 基于数据挖掘的中医药治疗原发性胆汁性胆管炎用药规律研究[J]. 中药新药与临床药理, 2022, 33( 8): 1124- 1130. DOI: 10.19378/j.issn.1003-9783.2022.08.017.
    [36]
    YOU LP, ZHENG C, GAO YQ, et al. Effect of zimian formula combined with ursodeoxycholic acid in treatment of primary biliary cholangitis patients with Gan-Shen Yin deficiency syndrome: A randomized controlled trial[J]. Chin J Integr Tradit West Med, 2023, 43( 3): 292- 297. DOI: 10.7661/j.cjim.20220905.318.

    游丽萍, 郑超, 高月求, 等. 自免方联合熊去氧胆酸治疗肝肾阴虚证原发性胆汁性胆管炎随机对照研究[J]. 中国中西医结合杂志, 2023, 43( 3): 292- 297. DOI: 10.7661/j.cjim.20220905.318.
    [37]
    CHEN YY, ZHENG YQ, SHI Z, et al. Effects of Modified Yinchenhao Decoction on liver fibrosis in patients of primary biliary cholangitis with poor response to UDCA[J]. Acad J Shanghai Univ Tradit Chin Med, 2021, 35( 3): 28- 32. DOI: 10.16306/j.1008-861x.2021.03.006.

    陈逸云, 郑玥琪, 时桢, 等. 加味茵陈蒿汤对UDCA应答不佳的原发性胆汁性胆管炎患者肝纤维化的影响[J]. 上海中医药大学学报, 2021, 35( 3): 28- 32. DOI: 10.16306/j.1008-861x.2021.03.006.
    [38]
    ZHENG YJ, TANG HH, HE JS, et al. Clinical efficacy of ursodeoxycholic acid combined with modified Artemisiae Scopariae Decoction for treating 30 cases of primary biliary cirrhosis[J]. Chin J Integr Tradit West Med Liver Dis, 2012, 22( 2): 89- 91. DOI: 10.3969/j.issn.1005-0264.2012.02.008.

    郑颖俊, 唐海鸿, 贺劲松, 等. 加味茵陈蒿汤联合熊去氧胆酸治疗原发性胆汁性肝硬化的临床研究[J]. 中西医结合肝病杂志, 2012, 22( 2): 89- 91. DOI: 10.3969/j.issn.1005-0264.2012.02.008.
    [39]
    LI M, LI ZQ, DENG ZZ. Treatment of 30 cases of primary biliary cirrhosis by activating blood circulation and removing blood stasis combined with ursodeoxycholic acid capsule[J]. Jiangxi J Tradit Chin Med, 2010, 41( 8): 39- 42. DOI: 10.3969/j.issn.0411-9584.2010.08.018.

    李猛, 李振前, 邓治正. 活血化瘀法联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化30例[J]. 江西中医药, 2010, 41( 8): 39- 42. DOI: 10.3969/j.issn.0411-9584.2010.08.018.
    [40]
    CHEN J, HUANG CY, HUANG YL, et al. Effect of Rhubarb choleretic capsule on the treatment of primary biliary cholangitis with ursodeoxycholic acid[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30( 6): 492- 494. DOI: 10.3969/j.issn.1005-0264.2020.06.002.

    陈杰, 黄春洋, 黄云丽, 等. 大黄利胆胶囊对熊去氧胆酸经治的原发性胆汁性胆管炎患者的临床观察[J]. 中西医结合肝病杂志, 2020, 30( 6): 492- 494. DOI: 10.3969/j.issn.1005-0264.2020.06.002.
    [41]
    QU Y, XIAO Z, CAO H, et al. Clinical study on the treatment of primary biliary cholangitis with poor response to ursodeoxycholic acid by“Tiaomian Formula I”[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29( 6): 493- 496. DOI: 10.3969/j.issn.1005-0264.2019.06.005.

    屈瑶, 肖臻, 曹辉, 等.“ 调免Ⅰ号方”治疗熊去氧胆酸应答不佳的原发性胆汁性胆管炎的临床研究[J]. 中西医结合肝病杂志, 2019, 29( 6): 493- 496. DOI: 10.3969/j.issn.1005-0264.2019.06.005.
    [42]
    WANG XJ, LIU Y, WANG XB. Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis[J]. J Clin Hepatol, 2020, 36( 1): 26- 30. DOI: 10.3969/j.issn.1001-5256.2020.01.004.

    王晓静, 刘尧, 王宪波. 原发性胆汁性胆管炎的熊去氧胆酸生化应答预测及中西医结合治疗[J]. 临床肝胆病杂志, 2020, 36( 1): 26- 30. DOI: 10.3969/j.issn.1001-5256.2020.01.004.
    [43]
    LIU Y, GAO FY, CHEN JL, et al. Effect of Shugan Lidan Jianpi Recipe on high risk patients with poor biochemical response to primary cholangitis[J]. Beijing J Tradit Chin Med, 2024, 43( 6): 586- 589. DOI: 10.16025/j.1674-1307.2024.06.002.

    刘尧, 高方媛, 陈佳良, 等. 疏肝利胆健脾方对原发性胆汁性胆管炎生化应答不佳高风险患者的疗效观察[J]. 北京中医药, 2024, 43( 6): 586- 589. DOI: 10.16025/j.1674-1307.2024.06.002.
    [44]
    WANG XB, BI YF, SHI K, et al. Therapeutic effect and mechanism of compound Chinese herbal medicines combined with UDCA on primary biliary cholangitis[J]. Beijing J Tradit Chin Med, 2024, 43( 6): 582- 585. DOI: 10.16025/j.1674-1307.2024.06.001.

    王宪波, 毕于斐, 时克, 等. 复方中药联合熊去氧胆酸治疗原发性胆汁性胆管炎临床疗效与作用机制[J]. 北京中医药, 2024, 43( 6): 582- 585. DOI: 10.16025/j.1674-1307.2024.06.001.
    [45]
    SHAO L, ZOU Y, GU YY. Clinical observation on Babao mini-pills combined with ursodeoxycholic acid capsules in the treatment of primary biliary cirrhosis[J]. Chin Med Mod Distance Educ China, 2020, 18( 19): 86- 88. DOI: 10.3969/j.issn.1672-2779.2020.19.035.

    邵丽, 邹勇, 顾友谊. 八宝丹联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化临床观察[J]. 中国中医药现代远程教育, 2020, 18( 19): 86- 88. DOI: 10.3969/j.issn.1672-2779.2020.19.035.
    [46]
    WANG Y, YUAN HL, MA XM, et al. Effects of kuhuang injection combined with ursodeoxycholic acid on liver function, immune factors and inflammatory mediators in patients with primary biliary cholangitis[J]. China J Pharm Econ, 2021, 16( 6): 31- 34, 43. DOI: 10.12010/j.issn.1673-5846.2021.06.006.

    王瑛, 袁鹤立, 马向明, 等. 苦黄注射液联合熊去氧胆酸对原发性胆汁性肝硬化患者肝功能、免疫因子及炎症介质水平的影响[J]. 中国药物经济学, 2021, 16( 6): 31- 34, 43. DOI: 10.12010/j.issn.1673-5846.2021.06.006.
    [47]
    ZHU HB. Observation on therapeutic effect of ursodeoxycholic acid combined with Yinzhihuang on primary biliary cirrhosis[J]. Acta Agric Shanghai, 2010, 27( 10): 1964- 1965. DOI: 10.3969/j.issn.1671-7171.2010.10.068.

    朱华波. 熊去氧胆酸联合茵栀黄治疗原发性胆汁性肝硬化疗效观察[J]. 医学临床研究, 2010, 27( 10): 1964- 1965. DOI: 10.3969/j.issn.1671-7171.2010.10.068.
    [48]
    MA RH, HUANG YQ, YANG JQ. Clinical study on Hugan Tablets combined with ademetionine 1, 4-butanedisulfonate in treatment of primary biliary cirrhosis[J]. Drugs Clin, 2019, 34( 3): 705- 708. DOI: 10.7501/j.issn.1674-5515.2019.03.028.

    马瑞宏, 黄颖秋, 杨金秋. 护肝片联合丁二磺酸腺苷蛋氨酸治疗原发性胆汁性肝硬化的临床研究[J]. 现代药物与临床, 2019, 34( 3): 705- 708. DOI: 10.7501/j.issn.1674-5515.2019.03.028.
    [49]
    BI YF, SHI K, CHEN JL, et al. Curative effect of anti-fibrosis Chinese patent medicines combined with ursodeoxycholic acid for primary biliary cholangitis: A systematic review and meta-analysis[J]. Front Pharmacol, 2023, 14: 1159222. DOI: 10.3389/fphar.2023.1159222.
    [50]
    HUANG LY, ZHOU ZH, SUN XH, et al. Clinical efficacy of Biejiaruangan compound tablets in treatment of primary biliary cirrhosis[J]. J Clin Hepatol, 2015, 31( 2): 181- 184. DOI: 10.3969/j.issn.1001-5256.2015.02.009.

    黄凌鹰, 周振华, 孙学华, 等. 复方鳖甲软肝片治疗原发性胆汁性肝硬化的临床疗效评价[J]. 临床肝胆病杂志, 2015, 31( 2): 181- 184. DOI: 10.3969/j.issn.1001-5256.2015.02.009.
    [51]
    WU Y, YAO DK, ZHU L, et al. Clinical observation on the safety and efficacy of ursodeoxycholic acid and fuzheng Huayu capsule in the treatment of primary biliary cirrhosis[J]. Chin J Integr Tradit West Med, 2012, 32( 11): 1477- 1482.

    吴颖, 姚定康, 朱樑, 等. 熊去氧胆酸联合扶正化瘀胶囊治疗原发性胆汁性肝硬化临床观察[J]. 中国中西医结合杂志, 2012, 32( 11): 1477- 1482.
    [52]
    QIU HQ, RAO LP. Anluo Huaxian pill in treatment of primary biliary cirrhosis patients and influence on index of immunology[J]. Chin Arch Tradit Chin Med, 2015, 33( 12): 2922- 2925. DOI: 10.13193/j.issn.1673-7717.2015.12.029.

    邱慧卿, 饶立萍. 安络化纤丸治疗原发性胆汁性肝硬化及对患者免疫学指标的影响[J]. 中华中医药学刊, 2015, 33( 12): 2922- 2925. DOI: 10.13193/j.issn.1673-7717.2015.12.029.
    [53]
    ZHAO J, CAO J, YAO DK. Research advances in pathogenesis and management of fatigue in patients with primary biliary cirrhosis[J]. J Clin Hepatol, 2016, 32( 11): 2218- 2221. DOI: 10.3969/j.issn.1001-5256.2016.11.050.

    赵健, 曹嘉, 姚定康. 原发性胆汁性胆管炎乏力机制与治疗进展[J]. 临床肝胆病杂志, 2016, 32( 11): 2218- 2221. DOI: 10.3969/j.issn.1001-5256.2016.11.050.
    [54]
    ZENG WW, WU XJ. Effect of Hugan Zhuyu Decoction combined with ursodeoxycholic acid on immunoglobulin and T lymphocyte subsets in patients with primary biliary cirrhosis[J]. Chin J Gen Pract, 2019, 17( 3): 464- 467. DOI: 10.16766/j.cnki.issn.1674-4152.000709.

    曾武武, 吴学杰. 护肝逐瘀汤联合熊去氧胆酸对原发性胆汁性肝硬化患者免疫球蛋白及T淋巴细胞亚群的影响[J]. 中华全科医学, 2019, 17( 3): 464- 467. DOI: 10.16766/j.cnki.issn.1674-4152.000709.
    [55]
    HUANG Y, XU GS, YANG PJ, et al. Effects of Zishui Hanmu Lidan Decoction on T helper 17 cells and Th17-related cytokines in patients with primary bil-iary cholangitis of liver and kidney deficiency type[J]. Hebei J Tradit Chin Med, 2022, 44( 5): 748- 753. DOI: 10.3969/j.issn.1002-2619.2022.05.010.

    黄祎, 许国圣, 杨浦娟, 等. 滋水涵木利胆方对肝肾亏虚型原发性胆汁性胆管炎患者外周血辅助性T淋巴细胞17及相关细胞因子的影响[J]. 河北中医, 2022, 44( 5): 748- 753. DOI: 10.3969/j.issn.1002-2619.2022.05.010.
    [56]
    CHEN XQ, CAO HF. Regulatory effect of Lidan Qushi recipe on T cell subsets in peripheral blood of patients with primary biliary cirrhosis of hepatobiliary damp-heat type[J]. J Sichuan Tradit Chin Med, 2018, 36( 11): 103- 105.

    陈秀清, 曹海芳. 利胆祛湿方对肝胆湿热型原发性胆汁性肝硬化患者外周血T细胞亚群的调节作用[J]. 四川中医, 2018, 36( 11): 103- 105.
    [57]
    BIAN M, DENG ZH. Bile acids are associated with pruritus in primary biliary cholangitis[J]. Chin J Gastroenterol Hepatol, 2024, 33( 1): 106- 109. DOI: 10.3969/j.issn.1006-5709.2024.01.022.

    边美, 邓志华. 胆汁酸与原发性胆汁性胆管炎相关瘙痒[J]. 胃肠病学和肝病学杂志, 2024, 33( 1): 106- 109. DOI: 10.3969/j.issn.1006-5709.2024.01.022.
    [58]
    CHEN YF, WANG LJ, XUE BY. Discussion on TCM syndrome differentiation and treatment of primary biliary cirrhosis with pruritus as the first symptom[J]. Jilin J Chin Med, 2013, 33( 4): 343- 345. DOI: 10.3969/j.issn.1003-5699.2013.04.011.

    陈宇锋, 王陆军, 薛博瑜. 以皮肤瘙痒为首发症状的原发性胆汁性肝硬化中医证治探讨[J]. 吉林中医药, 2013, 33( 4): 343- 345. DOI: 10.3969/j.issn.1003-5699.2013.04.011.
    [59]
    JIAO BJ, HAN LJ, WAN SQ. 30 cases of pruritus caused by cholestasis cirrhosis treated by traditional Chinese medicine for promoting blood circulation and removing blood stasis[J]. Shaanxi J Tradit Chin Med, 2013, 34( 1): 18- 19. DOI: 10.3969/j.issn.1000-7369.2013.01.009.

    焦宝娟, 韩丽静, 万树全. 活血化瘀中药为主治疗胆汁淤积性肝硬化瘙痒症30例[J]. 陕西中医, 2013, 34( 1): 18- 19. DOI: 10.3969/j.issn.1000-7369.2013.01.009.
    [60]
    LI SD, XU CJ, LIU Y, et al. Discussion on syndrome differentiation and treatment of chronic liver disease patients complicated with skin itching[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 5): 462- 464. DOI: 10.3969/j.issn.1005-0264.2021.05.022.

    李尚点, 徐春军, 刘尧, 等. 慢性肝病患者合并皮肤瘙痒证治探讨[J]. 中西医结合肝病杂志, 2021, 31( 5): 462- 464. DOI: 10.3969/j.issn.1005-0264.2021.05.022.
    [61]
    LI SG, PAN Q, JIANG LP, et al. She medicine(畲药)diren zishen formula(地稔滋肾方)combined with acupuncture as adjunctive treatment for 32 cases of primary biliary cholangitis with liver and kidney Yin deficiency syndrome[J]. J Tradit Chin Med, 2024, 65( 2): 198- 204. DOI: 10.13288/j.11-2166/r.2024.02.014.

    李诗国, 潘铨, 江丽平, 等. 畲药地稔滋肾方联合针刺辅助治疗原发性胆汁性胆管炎肝肾阴虚证32例临床观察[J]. 中医杂志, 2024, 65( 2): 198- 204. DOI: 10.13288/j.11-2166/r.2024.02.014.
    [62]
    CHEN JQ, YANG JY, ZHANG Y, et al. A randomized controlled trial on the treatment of primary Sjögren syndrome with Yin deficiency and dryness-heat pattern with Bushen Qingre Runzao Decoction[J]. J Beijing Univ Tradit Chin Med, 2023, 46( 11): 1490- 1498. DOI: 10.3969/j.issn.1006-2157.2023.11.002.

    陈嘉琪, 杨建英, 张燕, 等. 补肾清热润燥汤治疗原发性干燥综合征阴虚燥热证的随机对照研究[J]. 北京中医药大学学报, 2023, 46( 11): 1490- 1498. DOI: 10.3969/j.issn.1006-2157.2023.11.002.
    [63]
    WU ZH, HUANG ZW, CHEN JQ, et al. Effect of Huashi Runzao prescription on primary sjögren’s syndrome[J]. Chin J Exp Tradit Med Formulae, 2023, 29( 8): 45- 51. DOI: 10.13422/j.cnki.syfjx.20231593.

    吴子华, 黄子玮, 陈嘉琪, 等. 化湿润燥方治疗原发性干燥综合征的临床疗效[J]. 中国实验方剂学杂志, 2023, 29( 8): 45- 51. DOI: 10.13422/j.cnki.syfjx.20231593.
    [64]
    MONTAGNESE S, NSEMI LM, CAZZAGON N, et al. Sleep-Wake profiles in patients with primary biliary cirrhosis[J]. Liver Int, 2013, 33( 2): 203- 209. DOI: 10.1111/liv.12026.
    [65]
    XIONG NX, YUAN KW, XU JL, et al. Research progress on insomnia treated by traditional Chinese medicine[J]. Jiangxi J Tradit Chin Med, 2023, 54( 12): 72- 75.

    熊乃鑫, 袁可望, 徐佳玲, 等. 失眠从中医药论治研究进展[J]. 江西中医药, 2023, 54( 12): 72- 75.
    [66]
    HONG YB, LUO HC, YAO WH, et al. Clinical observation on 31 cases of insomnia treated by Chinese drug Jieyu pills[J]. J Tradit Chin Med, 2004, 45( 11): 843- 845. DOI: 10.3321/j.issn: 1001-1668.2004.11.024.

    洪永波, 罗和春, 姚卫海, 等. 中药解郁丸治疗失眠31例临床观察[J]. 中医杂志, 2004, 45( 11): 843- 845. DOI: 10.3321/j.issn: 1001-1668.2004.11.024.
    [67]
    XU JG, YU DX, ZHAO JP. Comparative Study of Jieyu Pill and alprazolam in the treatment of generalized anxiety disorder[J]. J Neuro Mental Health, 2005, 5( 4): 297- 298. DOI: 10.3969/j.issn.1009-6574.2005.04.024.

    徐建国, 于得霞, 赵俊平. 解郁丸、阿普唑仑治疗广泛性焦虑症临床对照研究[J]. 神经疾病与精神卫生, 2005, 5( 4): 297- 298. DOI: 10.3969/j.issn.1009-6574.2005.04.024.
    [68]
    ZHANG LF, ZHAN SH. Observation on the therapeutic effect of Jieyu pill and Shule Anding Tablet on insomnia[J]. Chin J Integr Med Cardio Cerebrovasc Dis, 2010, 8( 12): 1461- 1462. DOI: 10.3969/j.issn.1672-1349.2010.12.030.

    张鲁峰, 詹三华. 中药解郁丸与舒乐安定片治疗失眠疗效观察[J]. 中西医结合心脑血管病杂志, 2010, 8( 12): 1461- 1462. DOI: 10.3969/j.issn.1672-1349.2010.12.030.
    [69]
    JIANG B, MA ZH, ZUO F. Auricular acupuncture for insomnia: A randomized controlled trial[J]. Chin J Epidemiol, 2010, 31( 12): 1400- 1402. DOI: 10.3760/cma.j.issn.0254-6450.2010.12.017.

    姜斌, 马朱红, 左芳. 耳穴贴压疗法治疗失眠症的随机对照研究[J]. 中华流行病学杂志, 2010, 31( 12): 1400- 1402. DOI: 10.3760/cma.j.issn.0254-6450.2010.12.017.
    [70]
    XU Z, ZHU LQ. Effect of burying beans in auricular points on patients with chronic hepatitis and insomnia[J]. Chin J Gerontol, 2014, 34( 10): 2880- 2882. DOI: 10.3969/j.issn.1005-9202.2014.10.132.

    徐征, 朱丽群. 耳穴埋豆治疗慢性肝炎伴失眠症患者的效果[J]. 中国老年学杂志, 2014, 34( 10): 2880- 2882. DOI: 10.3969/j.issn.1005-9202.2014.10.132.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (276) PDF downloads(132) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return